Bas Groot Koerkamp retweeted
🔥off the press🔥
Pre-Liver Transplant Immunotherapy and Post-Transplant Outcomes in HCC: Global LIFT-HCC-1 Study
doi.org/10.1016/j.cgh.2026.0…
👉408 pts
👉Tumor burden & AFP at LT associated with HCC recurrence
👉Rejection associated with non-HBV, irAEs, age, shorter ICI washout
🧐pre-LT ICI feasible, clinical utility needs to be established
@myESMO @EASLnews @ILCAnews
Bas Groot Koerkamp retweeted
Privilege of the podium in Singapore with legends in HPB Surgery! @IHPBA @BasGrootKoerkam @MonicaDuaMD @ElenaPanettier1
@MedStarGUH @MedStarWHC @MedStarHealth @LombardiCancer
Bas Groot Koerkamp retweeted
Final analysis LEAP012 unresectable #HCC TACE +Len/Pembro v TACE
➡️mPFS 14.6 v 10.2 HR 0.7
➡️ORR 71 v 49% by mRECIST
❎mOS 40.4 v 40.6; ~1/3 in both subsequent tx
❎much higher gd3/4 TRAEs 71%v31%
➡️❗️1/3 BCLCA
➡️Role combo unclear consistent -ve OS
@myESMO #ESMO26 @OncoAlert
Bas Groot Koerkamp retweeted
Replying to @SaborowskiAnna
@SaborowskiAnna putting into the context abstracts on #HCC from intermediate to advanced stage, from #TACE+immunotherapy to #CAR-T at #ESMO26 #ESMOAmbassadors @myESMO
Bas Groot Koerkamp retweeted
Congrats to Dr. @vikram_chaudhari for leading the Delphi consensus process for gallbladder classification at @IHPBA . Honored to participate.
@Shrikhande_SV @TataMemorial
Bas Groot Koerkamp retweeted
HRS-4642 plus CTx ± adebrelimab as perioperative therapy in KRAS G12D-mPDAC: Preliminary results of a phase 2 study
#ESMO26 #ESMOAmbassadors
👉ORR: 63 vs 87%
👉Manageable safety
🧐 exciting results, tumor shrinkage in all pts, added benefit of ICI remains to be seen
@myESMO @ASCO
Bas Groot Koerkamp retweeted
Lots of hard work moving this project forward - SAFIR-IMPACT-BTC
📸Meeting at @myESMO #ESMO26
Delighted to see how #AcademicResearch brings people together
😊We are a very close and collaborative research community, working together to improve outcomes in #BiliaryMalignancies
🔔Great news! #Funded projects #ATTRACT2025
𝗦𝗔𝗙𝗜𝗥 𝗜𝗠𝗣𝗔𝗖𝗧 𝗕𝗧𝗖 - PhIII - Precision Medicine Adjuvant #BiliaryMalignancies
𝗖𝗼𝗼𝗿𝗱𝗶𝗻𝗮𝘁𝗼𝗿: #JulienEdeline
𝗖𝗼𝗻𝘀𝗼𝗿𝘁𝗶𝘂𝗺: 🇫🇷🇪🇸🇧🇪🇳🇱
Spain. Led by 🙋🏻♀️, @Hospital_FJD @GrupoTTD @ContraCancerEs
Bas Groot Koerkamp retweeted
Tomorrow at #ESMO26: MSK hepatopancreatobiliary surgeon Dr. Vinod Balachandran (@TheVinodLab) will discuss immunotherapy in pancreatic cancer and overcoming barriers to success.
🗓️ Monday, October 26 | 11:15 a.m. CET
Bas Groot Koerkamp retweeted
Masterful talk @BasGrootKoerkam on localised #PDAC & #BTC 🔑points👇
➡️PDAC staging requires anatomy/biology/clinical ass
➡️?older patients benefit NAC
➡️hilar obs➡️perc stenting TESLA
➡️high risk iCCA consider NAC
➡️LRT & Liver tx evolving in iCCA
@myESMO #ESMO26 @OncoAlert
Bas Groot Koerkamp retweeted
🔬Ivonescimab now represent a promising emerging therapeutic option - exciting progress for cholangiocarcinoma and biliary tract cancer patients @curecc
HARMONI-GI1 at the @myESMO #ESMO26 #Presidential of CisGem + #ivonescimab vs durvalumab in #firstline #BiliaryMalignancies
✅OS HR 0.75, mOS 12.1vs14.9
✅PFS HR 0.61, mPFS 6.8vs8.4
✅ORR 53.8vs32.5
🌐China only
BUT
😊This is a positive trial
🥳VEGF is back
#ESMOAmbassadors
Bas Groot Koerkamp retweeted
The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology
@Annals_Oncology
doi.org/10.1016/j.annonc.202…
👉helpful for interpreting actionability and decision making
@myESMO @ASCO
Bas Groot Koerkamp retweeted
Which approach offers safer biliary drainage?
See the #UEGWeek findings from “Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT” 🔎
Bas Groot Koerkamp retweeted
Video-based assessment identified a learning curve of approximately 34 robotic gastroenterostomies during pancreatoduodenectomy, with rates of clinically relevant delayed gastric emptying declining from 25.7% to 11.5% after the learning curve. ovid.com/10.1097/SLA.0000000…
Bas Groot Koerkamp retweeted
The TESLA trial - my highlight at today’s late breaking abstract session at #UEGWeek
Question: For malignant hilar obstruction, which is better: percutaneous drainage (PTC) or endoscopic drainage (ERCP)?
Result: PTC > ERCP for unresectable hilar strictures.
Bas Groot Koerkamp retweeted
What is the optimal duration of antibiotics after ERCP decompression for cholangitis?
The #UEGWeek 2026 top abstract prize goes to Anouk Overdevest for her work on the COBRA trial, which shows that 1 day of antibiotic is non-inferior to 4-7 day courses 👏🏆
🤖 Made with AI
Bas Groot Koerkamp retweeted
5 Pancreatic Cancer Trials to Watch at ESMO 2026
The ESMO Congress 2026 will feature new pancreatic cancer data across resected, borderline resectable, locally advanced, and metastatic disease.
Trials to watch:
• RASolute 302 — Additional subgroup analyses of daraxonrasib vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma
• AMPLIFY-7P — Randomized phase II results with ELI-002 7P vs observation in resected pancreatic ductal adenocarcinoma
• MASTERPLAN — mFOLFIRINOX with or without SBRT in patients with high-risk, borderline resectable, or locally advanced pancreatic cancer
• HRS-4642 — Preliminary phase II results with HRS-4642 + chemotherapy ± adebrelimab as perioperative therapy in KRAS G12D-mutant pancreatic cancer
• INCB161734 — Safety and efficacy of INCB161734 in combination with chemotherapy in advanced or metastatic pancreatic ductal adenocarcinoma
Together, these five presentations will provide additional data across resected, locally advanced, and metastatic pancreatic cancer, including several RAS-directed treatment strategies.
@AHollebecque @WainbergZev @EileenMOReilly
📎oncodaily.com/gastrointestin…
#ESMO2026 #KRAS #OncoDaily
Bas Groot Koerkamp retweeted
🔥off the press🔥
Overall and Line-Specific Impact of Targeted Therapies in Advanced BTC After Chemoimmunotherapy Failure
@JHepatology
doi.org/10.1016/j.jhep.2026.…
👉continuous evidence for 🎯💊in BTC
🧐we need to make sure that these therapies are accessible to all (!) patients
@myESMO @ASCOPost @EASLedu @ILCAnews
Bas Groot Koerkamp retweeted
Proud of our @nyulangone Dean (and prior @Perlmutter_CC Director) Alec Kimmelman for his @Nature paper today:
Hepatocytes promote liver metastasis of #PancreaticCancer by providing serine
nature.com/articles/s41586-0…
With @BarDafna @RichPossemato @KoelinaG @nyugrossman
Bas Groot Koerkamp retweeted
📝 #JAMAReview: #LiquidBiopsy using circulating #tumor #DNA can help guide care in #Cancer by identifying gene variants associated with treatment selection, monitoring treatment response, and detecting minimal residual disease after therapy.
Detectable circulating tumor DNA after curative-intent treatment was associated with recurrence and poorer survival across multiple cancer settings, often before progression was evident on imaging.
ja.ma/4dFgtVU
The use of locoregional therapies in cholangiocarcinoma - JHep Oct 2026 sciencedirect.com/science/ar… @curecc @CharityAMMF @EASLnews @ENS_CCA























































